Prostate Cancer

Sign up for our COVID-19 newsletter to stay up-to-date on the latest coronavirus news throughout New York Prostate cancer is a formidable foe that kills tens of thousands of men every year.  The World Cancer Research Fund International notes that age-adjusted incidence rates of prostate cancer have increased dramatically, citing the increased availability of screening for prostate-specific antigen, or PSA, for helping to find prostate cancer in men who otherwise might never know they were sick. In fact, the Prostate Cancer Foundation notes that there usually aren’t any early warning signs for prostate cancer, which only highlights the importance of routine screenings. Tumors resulting from prostate cancer may not push against anything to cause pain, even as they are growing. So men who do not receive routine prostate cancer screenings may live for years with the disease without knowing it. Such screenings can be a great ally in the fight against prostate cancer, but men can also re

GERMANTOWN, Md. , Aug. 31, 2020 /PRNewswire/ -- The HealthWell Foundation ® , an independent non-profit that provides a financial lifeline for inadequately insured Americans, has launched a new fund to provide copayment and premium assistance to Medicare patients living with prostate cancer. Through the fund, HealthWell will provide up to $8,000 in financial assistance for a 12-month grant period to eligible patients who have annual household incomes up to 500 percent of the federal poverty level. "A prostate cancer diagnosis can be overwhelming, scary, and costly. HealthWell's new copay assistance program is a welcomed option to help patients better afford their prescribed treatment. Especially during the COVID-19 pandemic, financial barriers are more stressful than ever, and this new fund will provide a critical safety net for patients in need," said Jamie Bearse , CEO of ZERO - The End of Prostate Cancer. Prostate cancer begins when cells in the prostate gland star

As the rates of high-risk prostate cancer in the U.S. increased in recent years, use of prostatectomy nearly doubled while radiotherapy declined, new research from the National Cancer Database (NCDB) found. From 2004 to 2016, the proportion of prostate cancer cases classified as high risk increased from 11.8% to 20.4%, and use of prostatectomy in this population rose from 22.8% to 40.5% during this time ( P <0.001 for both), according to Himanshu Nagar, MD, a radiation oncologist at Weill Cornell Medicine in New York City, and colleagues. This increase in surgery was met with declines in radiotherapy use for high-risk patients, which fell from 59.7% to 43.3% over this stretch of time ( P <0.001), the group reported in JAMA Network Open . These shifts in treatment patterns have taken place without guideline evidence suggesting superiority of prostatectomy, Nagar's group noted. "The increasing use of robotic approaches suggests urologists and patients may regard prosta

Sign up for our COVID-19 newsletter to stay up-to-date on the latest coronavirus news throughout New York A Stony Brook University-led research team is investigating a new prostate cancer treatment that could offer an alternative to chemotherapy without the adverse effects on patients or tumors building up a resistance.  The research is testing a fatty acid-binding protein (FABP) in the treatment of inflammation, pain, and halting the spread of certain cancers as drug targets themselves, or in combination with chemotherapy treatments such as docetaxel or cabazitaxel, a class of drugs known as taxanes. “In our research, neither docetaxel or cabazitaxel alone was able to eradicate prostate cancer cells in vitro, while combinations of taxanes with FABP5 inhibitors resulted in complete prostate cell death with synergism at very low concentrations of taxanes,” said Iwao Ojima, Ph.D., the lead investigator and director of SBU’s Institute of Chemical Biology and Drug Discovery. The study

Some patients with low-risk prostate cancer (PCa) receiving active surveillance (AS) can safely adopt a less intensive monitoring regimen after confirmatory biopsy, investigators suggest. Matthew R. Cooperberg, MD, MPH, of the University of California, San Francisco (UCSF), and colleagues developed and validated the Canary model, a potential clinical tool that can be used to identify AS patients at very low risk or high risk for PCa reclassification at confirmatory biopsy, which is within a year of diagnosis at their institution. Eligible men had Gleason grade group (GG) 1 on diagnostic biopsy and GG1 (Gleason score 3+3) or no tumor on first surveillance biopsy. Reclassification was defined as any increase to GG 2 (Gleason score 3+4) or higher. The model was developed using routinely collected clinical data from the Canary Prostate Active Surveillance Study (PASS) cohort of 850 men (median age 64 years; 91% White). It was validated using a separate UCSF cohort of 533 men (median a

In   “Journal Article of the Month,"   Badar M. Mian, MD,   offers perspective on noteworthy research in the peer-reviewed literature. Dr. Mian is professor of surgery in the division of urology at Albany Medical College, New York. Active surveillance of low-risk prostate cancer, with the intention to delay or avoid any treatment-related adverse effects, has been employed with increasing frequency over the past decade. However, concerns remain about disease progression and loss of opportunity to cure an otherwise curable disease. To address these concerns, Ahmad et al report on their experience and outcomes from delayed radical prostatectomy (RP) in men who were initially diagnosed with low-risk prostate cancer and managed with active surveillance (AS). 1 The authors reviewed their AS cohort of 1359 men from 1992 and 2015 at Princess Margaret Cancer Centre in Toronto, Ontario, Canada, and identified 294 (21.6%) who were treated with RP due to disease progression. Of these, 170

Germline genetic testing is a key component of prostate cancer treatment, and broader testing criteria combined with reduced barriers to these tests could result in better informed care, including preventive surveillance, according to data from a recent study. 1 Results from the retrospective study done in a total of 986 patients with prostate cancer who participated in a sponsored testing program showed that 16% (n = 153) of patients who underwent genetic testing had positive germline result; of these patients, 14% (n = 138) had pathogenic (P)/likely pathogenic (LP) variants and 1.5% (n = 15) had increased risk alleles (IRAs). Moreover, these patients were found to have 167 P/LP variants in 31 genes, as well as 19 IRAs in APC and HOXB13. A total of 129 patients with P/LP variants had staging data available. This information indicated that 70 patients had very high-risk disease (stage III/IV), 23 had high-risk disease (stage III), and 36 had intermediate- to low-risk disease (stage

DUBLIN , Aug. 27, 2020 /PRNewswire/ -- The "US Prostate Cancer Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering. The "US Prostate Cancer Market and Competitive Landscape Highlights - 2020" report provides comprehensive insights into Prostate Cancer pipeline products, Prostate Cancer epidemiology, Prostate Cancer market valuations and forecast, Prostate Cancer drugs sales and competitive landscape in the US. The research is classified into seven sections - Prostate Cancer treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares. Research Scope: Prostate Cancer pipeline: Find out the products in clinical trials for the treatment of Prostate Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products Prostate Cancer epidemiology: Find out th

Latest released the research study on  Global Hormone Refractory Prostate Cancer Market, offers a detailed overview of the factors influencing the global business scope. Hormone Refractory Prostate Cancer Market research report shows the latest market insights, current situation analysis with upcoming trends and breakdown of the products and services. The report provides key statistics on the market status, size, share, growth factors of the Hormone Refractory Prostate Cancer Market. The study covers emerging player’s data, including: competitive landscape, sales, revenue and global market share of top manufacturers. Top players in Global Hormone Refractory Prostate Cancer Market are: AbbVie Inc. (United States) Acceleron Pharma Inc. (United States) AB Science SA (France) AstraZeneca Plc. (United Kingdom) Astellas Pharma Inc. (Japan) Boston Biomedical, Inc. (United States) Dendreon Corporation (United States) Sanofi S.A (France) Johnson & Johnson (United States)   Free

Germline genetic testing is a key component of prostate cancer treatment, and broader testing criteria combined with reduced barriers to these tests could result in better informed care, including preventive surveillance, according to data from a recent study. 1 Results from the retrospective study done in a total of 986 patients with prostate cancer who participated in a sponsored testing program showed that 16% (n = 153) of patients who underwent genetic testing had positive germline result; of these patients, 14% (n = 138) had pathogenic (P)/likely pathogenic (LP) variants and 1.5% (n = 15) had increased risk alleles (IRAs). Moreover, these patients were found to have 167 P/LP variants in 31 genes, as well as 19 IRAs in APC and HOXB13 . A total of 129 patients with P/LP variants had staging data available. This information indicated that 70 patients had very high-risk disease (stage III/IV), 23 had high-risk disease (stage III), and 36 had intermediate- to low-risk disease (stag

The FDA has approved FoundationOneLiquid CDx for use as a companion diagnostic with the PARP inhibitor rucaparib (Rubraca), which is approved by the FDA for the treatment of patients with BRCA­ mutation–positive metastatic castration-resistant prostate cancer (mCRPC). 1 The pan-tumor liquid biopsy test examines over 300 cancer-related genes in a patient’s blood sample to inspect for deleterious alterations. Foundation Medicine, the manufacturer of the diagnostic, reported in a press release that FoundationOneLiquid CDx is covered for eligible Medicare and Medicare Advantage beneficiaries. “Now that we have drugs that specifically benefit patients with  BRCA  mutations, the ability to identify who has these mutations is paramount,” Celestia S. Higano, MD, University of Washington School of Medicine, stated in a press release. 2 “In contrast to tissue biopsy, a liquid biopsy is a blood-plasma test that is less invasive than a tissue biopsy for assessing germline or somatic  BRCA  mu

The latest update of Global Castration Resistant Prostate Cancer Treatment Market study provides comprehensive information on the development activities by industry players, growth opportunities and market sizing for Castration Resistant Prostate Cancer Treatment, complete with analysis by key segments, leading and emerging players, and geographies. The 91 page study covers the detailed business overview of each profiled players, its complete research and market development history with latest news and press releases. The study helps in identifying and tracking emerging players in the market and their portfolios, to enhance decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Some of the players profiled/ part of study coverage are Active Biotech, Diagnocure, Glaxosmithkline, Northwest Biotherapeutics, Millennium Pharmaceuticals, Hologic, Spectrum Pharmaceuticals, Abbott Laboratories & Bayer Healthcare Pharmaceuticals. Get fr

The Scioto County Commissioners’ Resolution acknowledging September as Prostate Cancer Awareness Month Courtesy Photos September is Prostate Cancer Awareness Month and light blue ribbons are representative of this month. Courtesy Photos Our society seems to accept breast cancer awareness and uterine cancer awareness as part of our lives and have little problem talking about them, but when it comes to men and prostate awareness, it is not easily spoken of among people. Since prostate cancer is the number two cause of cancer death in men. The Scioto County Commissioners recently passed a resolution acknowledging September as prostate cancer awareness month. Commissioner Mike Crabtree made a motion to pass the resolution and Commissioner Cathy Coleman seconded that motion and all three members, including Commissioner Bryan Davis passed the resolution. National Prostate Health Month (NPHM), also known as National Prostate Cancer Awareness Month, is observed every September

 To evaluate the clinical therapeutic response of PSMA targeted radioligand therapy with 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. The current study analyzed disease-related quality of life (QoL) in patients undergoing PSMA therapy with a special focus on the association with simultaneous PSA response.  Thirty patients (age range 50-87 years, median 73.5 years) undergoing 177Lu-PSMA-617 therapy from 2014 to 2016 at our institution were included in this pilot study. Health-related QoL was assessed by EORTC QLQ-C30 questionnaire filled in at baseline and two months after initializing the PSMA-therapy. The treatment response was evaluated under three categories with regard to changes in (a) global health status and other functional scales, (b) disease-related symptoms, and (c) effects of PSA values.  Most patients underwent three treatment cycles (n = 12); at least 2 cycles (n = 6) or at most 8 cycles (n = 1) were performed. Out of 30 cases, PSA re

The Scioto County Commissioners’ Resolution acknowledging September as Prostate Cancer Awareness Month Courtesy Photos September is Prostate Cancer Awareness Month and light blue ribbons are representative of this month. Courtesy Photos Our society seems to accept breast cancer awareness and uterine cancer awareness as part of our lives and have little problem talking about them, but when it comes to men and prostate awareness, it is not easily spoken of among people. Since prostate cancer is the number two cause of cancer death in men. The Scioto County Commissioners recently passed a resolution acknowledging September as prostate cancer awareness month. Commissioner Mike Crabtree made a motion to pass the resolution and Commissioner Cathy Coleman seconded that motion and all three members, including Commissioner Bryan Davis passed the resolution. National Prostate Health Month (NPHM), also known as National Prostate Cancer Awareness Month, is observed every September

In this report, the global Prostate Cancer Treatment market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025. For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025. The Prostate Cancer Treatment market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world’s main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Prostate Cancer Treatment market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis. Requ

Men who have metastatic prostate cancer (PCa) at initial presentation are less likely to die from the malignancy compared with men who progress to metastatic PCa after initial therapy, according to a new study. The finding suggest that “these entities may have distinct biology informed by prior treatment exposure,” Hala T. Borno, MD, of the University of California, San Francisco, and collaborators concluded in a report published in Urologic Oncology . The study examined data from 14,753 patients in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry diagnosed with PCa from 1990 to 2016. Of these, 669 (5%) had metastatic disease: 303 (45%) at diagnosis (de novo metastatic PCa) and 366 (55%) who progressed to metastatic disease after initial therapy (recurrent metastatic PCa). The median follow-up time was 40 months for men with de novo metastatic PCa compared with 22 months for those with recurrent metastatic PCa. Among the patients with metastatic

Introduction:  To evaluate the clinical therapeutic response of PSMA targeted radioligand therapy with  177 Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. The current study analyzed disease-related quality of life (QoL) in patients undergoing PSMA therapy with a special focus on the association with simultaneous PSA response. Methods:  Thirty patients (age range 50-87 years, median 73.5 years) undergoing  177 Lu-PSMA-617 therapy from 2014 to 2016 at our institution were included in this pilot study. Health-related QoL was assessed by EORTC QLQ-C30 questionnaire filled in at baseline and two months after initializing the PSMA-therapy. The treatment response was evaluated under three categories with regard to changes in (a) global health status and other functional scales, (b) disease-related symptoms, and (c) effects of PSA values. Results:  Most patients underwent three treatment cycles (n = 12); at least 2 cycles (n = 6) or at most 8 cycles (n = 1) we

Dublin, Aug. 25, 2020 (GLOBE NEWSWIRE) -- The "US Prostate Cancer Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering. Prostate Cancer pipeline: Find out the products in clinical trials for the treatment of Prostate Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products Prostate Cancer epidemiology: Find out the number of patients diagnosed (prevalence) with Prostate Cancer in the US Prostate Cancer drugs: Identify key products marketed and prescribed for Prostate Cancer in the US, including trade name, molecule name, and company Prostate Cancer drugs sales: Find out the sales revenues of Prostate Cancer drugs in the US Prostate Cancer market valuations: Find out the market size for Prostate Cancer drugs in 2019 in the US. Find out how the market advanced from 2016 and forecast to 2025 Prostate Cancer drugs market share: Find out the market shares for key Prostate